Mylan to pay US government $465m over EpiPen

Mylan has agreed to pay the US Department of Justice and other government agencies $465 million to settle questions about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB year in review: A shifting landscape and outlook for 2026

2 January 2026 With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.

Americas

5 ways the USPTO director is changing US innovation

24 December 2025 John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.

Americas

Mirum targets generics in quartet of suits over liver treatment

22 December 2025 Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.

More features

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Mylan to pay US government $465m over EpiPen

More on this story

Editor's picks

Editor's picks

More features